Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M505465200 on July 14, 2005

J. Biol. Chem., Vol. 280, Issue 37, 32209-32217, September 16, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/37/32209    most recent
M505465200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yew, K.-H.
Right arrow Articles by Gittes, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yew, K.-H.
Right arrow Articles by Gittes, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cross-talk between Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling Is Essential for Exendin-4-induced Insulin-positive Differentiation of AR42J Cells*

Kok-Hooi Yew, Mark Hembree, Krishna Prasadan, Barry Preuett, Christopher McFall, Christina Benjes, Amanda Crowley, Susan Sharp, Sidhartha Tulachan, Sheilendra Mehta, Eri Tei, and George Gittes1

From the Department of Surgery Research, The Children's Mercy Hospital, Kansas City, Missouri 64108

A key goal of cellular engineering is to manipulate progenitor cells to become {beta}-cells, allowing cell replacement therapy to cure diabetes mellitus. As a paradigm for cell engineering, we have studied the molecular mechanisms by which AR42J cells become {beta}-cells. Bone morphogenetic proteins (BMPs), implicated in a myriad of developmental pathways, have not been well studied in insulin-positive differentiation. We found that the canonical intracellular mediators of BMP signaling, Smad-1 and Smad-8, were significantly elevated in AR42J cells undergoing insulin-positive differentiation in response to exendin-4 treatment, suggesting a role for BMP signaling in {beta}-cell formation. Similarly, endogenous BMP-2 ligand and ALK-1 receptor (activin receptor-like kinase-1; known to activate Smads 1 and 8) mRNAs were specifically up-regulated in exendin-4-treated AR42J cells. Surprisingly, Smad-1 and Smad-8 levels were suppressed by the addition of BMP-soluble receptor inhibition of BMP ligand binding to its receptor. Here, insulin-positive differentiation was also ablated. BMP-2 ligand antisense also strongly inhibited Smad-1 and Smad-8 expression, again with the abolition of insulin-positive differentiation. These results demonstrate a previously unrecognized key role for BMP signaling in mediating insulin-positive differentiation through the intracellular Smad signaling pathway. In short, BMP signaling may represent a novel downstream target of exendin-4 (glucagon-like peptide 1) signaling and potentially serve as an upstream regulator of transforming growth factor-{beta} isoform signaling to differentiate the acinar-like AR42J cells into insulin-secreting cells.


Received for publication, May 18, 2005 , and in revised form, July 8, 2005.

* This work was supported by National Institutes of Health Grants 1 R01 DK58400-01 and 1 R01 DK064952-01 to (G. K. G.) and Grant JDRF1 2-1999-636. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Children's Hospital of Pittsburgh, 3705 5th Ave., Pittsburgh, PA 15213. Tel.: 412-692-7283; E-mail: george.gittes{at}chp.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. Islam, N. Zhang, P. Wang, H. Li, P. L. Brubaker, H. Y. Gaisano, Q. Wang, and T. Jin
Epac is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic {alpha}- and intestinal L-cell lines
Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E174 - E181.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
W. Kim and J. M. Egan
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
N. Ota, S. Soga, T. Hase, I. Tokimitsu, and T. Murase
Dietary Diacylglycerol Induces the Regression of Atherosclerosis in Rabbits
J. Nutr., May 1, 2007; 137(5): 1194 - 1199.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
D. D. De Leon, C. Farzad, M. F. Crutchlow, J. Brestelli, J. Tobias, K. H. Kaestner, and D. A. Stoffers
Identification of transcriptional targets during pancreatic growth after partial pancreatectomy and exendin-4 treatment
Physiol Genomics, January 12, 2006; 24(2): 133 - 143.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement